Skip to main content
Terug
JXFGF logo

Jinxin Fertility Group Limited

Datakwaliteit: 100%
Overbought
JXFGF
OTC Healthcare Medical - Care Facilities
€ 0,29
€ 0,00 (0,00%)
Marktkapitalisatie: 782,54M
Dagbereik
€ 0,20 € 0,50
52-Weeksbereik
€ 0,20 € 0,50
Volume
1.323
50D / 200D Gem.
€ 0,29 / € 0,28
Vorige Slotkoers
€ 0,29

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 2,8 0,4
P/B 0,1 2,9
ROE % 2,8 3,7
Net Margin % 10,1 3,8
Rev Growth 5Y % 18,5 10,0
D/E 0,3 0,2

Belangrijkste Punten

Revenue grew 18,50% annually over 5 years — strong growth
Earnings declined -17,88% over the past year
ROE of 2,78% is below average
Debt/Equity of 0,25 — conservative balance sheet
Generating 366,84M in free cash flow
P/E of 2,76 — trading at a low valuation

Groei

Revenue Growth (5Y)
18,50%
Revenue (1Y)0,81%
Earnings (1Y)-17,88%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
2,78%
ROIC2,64%
Net Margin10,07%
Op. Margin16,14%

Veiligheid

Debt / Equity
0,25
Current Ratio0,51
Interest Coverage7,91

Waardering

P/E Ratio
2,76
P/B Ratio0,08
EV/EBITDA6,26
Dividend Yield0,03%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 0,81% Revenue Growth (3Y) 9,05%
Earnings Growth (1Y) -17,88% Earnings Growth (3Y) 52,88%
Revenue Growth (5Y) 18,50% Earnings Growth (5Y) 2,99%
Profitability
Revenue (TTM) 2,81B Net Income (TTM) 283,10M
ROE 2,78% ROA 1,89%
Gross Margin 39,10% Operating Margin 16,14%
Net Margin 10,07% Free Cash Flow (TTM) 366,84M
ROIC 2,64% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,25 Current Ratio 0,51
Interest Coverage 7,91 Dividend Yield 0,03%
Valuation
P/E Ratio 2,76 P/B Ratio 0,08
P/S Ratio 0,28 PEG Ratio -1,26
EV/EBITDA 6,26 Dividend Yield 0,03%
Market Cap 782,54M Enterprise Value 2,84B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 2,81B 2,79B 2,36B 1,84B 1,43B
Net Income 283,10M 344,72M 121,12M 339,90M 251,62M
EPS (Diluted) 0,10 0,12 0,05 0,14 0,10
Gross Profit 1,10B 1,18B 913,13M 771,48M 565,78M
Operating Income 453,92M 480,47M 285,37M 371,39M 237,68M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 14,98B 14,90B 15,23B 12,83B 9,16B
Total Liabilities 4,63B 4,71B 6,50B 4,07B 1,70B
Shareholders' Equity 10,27B 10,09B 8,64B 8,55B 7,28B
Total Debt 2,60B 2,55B 4,16B 2,09B 406,87M
Cash & Equivalents 546,20M 624,28M 1,33B 862,33M 681,62M
Current Assets 1,09B 1,34B 1,90B 2,54B 2,65B
Current Liabilities 2,12B 1,69B 2,76B 1,07B 555,08M

Strategiescores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#420 of 820
41
Value Defensive Investing (Benjamin Graham)
#87 of 708
57

Recente Activiteit

Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026